

# Letter of medical necessity checklist

If your patient's health insurance provider has coverage restrictions in place for LEQVIO<sup>®</sup>, a letter of medical necessity may be used to ensure your patients who need LEQVIO are able to receive it.

The checklist below is provided to help ensure your letter of medical necessity is as complete as possible when communicating with health plans. To view a sample letter of medical necessity, visit [LEQVIOhcp.com/resources](https://LEQVIOhcp.com/resources). The checklist is intended to provide examples of what information is usually required.

- ☐ Include patient's name, date of birth, insurance ID number, insurance group number, and dates of service
- ☐ Include relevant ICD-10 code(s) to support your diagnosis. Visit [LEQVIOhcp.com/resources](https://LEQVIOhcp.com/resources) for more information on coding, or see the [Billing and Coding Guide](#) for examples of codes that may be relevant to LEQVIO
- ☐ Clearly state the rationale for treatment with LEQVIO and why it is appropriate for the patient
- ☐ List current and previous therapies, or if the patient is intolerant to current therapies. Confirm that the patient has not achieved adequate results from current or prior therapy
- ☐ Provide clinical support for your recommendation. This can include information such as:
  - ☐ Clinical trial data from the [LEQVIO Prescribing Information](#)
  - ☐ Test results and chart notes (eg, LDL-C levels)
  - ☐ Relevant patient history regarding diet and exercise
  - ☐ Additional medical records
- ☐ Summarize your recommendation and provide a phone number in case any additional information is needed

For additional information and support, contact your Novartis representative or visit [LEQVIOhcp.com](https://LEQVIOhcp.com).

## INDICATION

LEQVIO injection is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

## IMPORTANT SAFETY INFORMATION

LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included angioedema. Adverse reactions in clinical trials ( $\geq 3\%$  of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click [here](#) for LEQVIO full Prescribing Information.

Licensed from Alnylam Pharmaceuticals, Inc.